Login / Signup

A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis.

Oliver PohlKyle BaronMatthew M RiggsJonathan FrenchRamon GarciaJean-Pierre Gotteland
Published in: British journal of clinical pharmacology (2022)
The previously-reported E2 target range (20-50 pg/mL) to balance efficacy and safety endpoints was confirmed. Linzagolix once daily doses between 75-125 mg daily were expected to meet endometriosis-associated pain, efficacy, and BMD loss targets in Caucasian patients.
Keyphrases